209 related articles for article (PubMed ID: 20937023)
1. Optimizing tumor-reactive γδ T cells for antibody-based cancer immunotherapy.
Meraviglia S; Caccamo N; Guggino G; Tolomeo M; Siragusa S; Stassi G; Dieli F
Curr Mol Med; 2010 Nov; 10(8):719-26. PubMed ID: 20937023
[TBL] [Abstract][Full Text] [Related]
2. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
Front Immunol; 2018; 9():2873. PubMed ID: 30574146
[TBL] [Abstract][Full Text] [Related]
3. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
4. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
[TBL] [Abstract][Full Text] [Related]
5. Improving Immunotherapy Against B-Cell Malignancies Using γδ T-Cell-specific Stimulation and Therapeutic Monoclonal Antibodies.
Hoeres T; Pretscher D; Holzmann E; Smetak M; Birkmann J; Triebel J; Bertsch T; Wilhelm M
J Immunother; 2019; 42(9):331-344. PubMed ID: 31318724
[TBL] [Abstract][Full Text] [Related]
6. Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.
Ochoa MC; Minute L; Rodriguez I; Garasa S; Perez-Ruiz E; Inogés S; Melero I; Berraondo P
Immunol Cell Biol; 2017 Apr; 95(4):347-355. PubMed ID: 28138156
[TBL] [Abstract][Full Text] [Related]
7. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies.
Gertner-Dardenne J; Bonnafous C; Bezombes C; Capietto AH; Scaglione V; Ingoure S; Cendron D; Gross E; Lepage JF; Quillet-Mary A; Ysebaert L; Laurent G; Sicard H; Fournié JJ
Blood; 2009 May; 113(20):4875-84. PubMed ID: 19278954
[TBL] [Abstract][Full Text] [Related]
8. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy.
Houot R; Kohrt HE; Marabelle A; Levy R
Trends Immunol; 2011 Nov; 32(11):510-6. PubMed ID: 21907000
[TBL] [Abstract][Full Text] [Related]
9. [Characterization of Therapeutic Monoclonal Antibodies by Using FcγR-expressing Reporter Cell Lines].
Tada M; Ishii-Watabe A
Yakugaku Zasshi; 2017; 137(7):837-843. PubMed ID: 28674297
[TBL] [Abstract][Full Text] [Related]
10. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
11. [Progress of study on antitumor effects of antibody dependent cell mediated cytotoxicity--review].
Qu YH; Li Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1370-5. PubMed ID: 21129296
[TBL] [Abstract][Full Text] [Related]
12. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
13. CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta.
Moretta A; Poggi A; Pende D; Tripodi G; Orengo AM; Pella N; Augugliaro R; Bottino C; Ciccone E; Moretta L
J Exp Med; 1991 Dec; 174(6):1393-8. PubMed ID: 1720808
[TBL] [Abstract][Full Text] [Related]
14. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
16. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.
Tang Y; Lou J; Alpaugh RK; Robinson MK; Marks JD; Weiner LM
J Immunol; 2007 Sep; 179(5):2815-23. PubMed ID: 17709495
[TBL] [Abstract][Full Text] [Related]
17. Stimulated γδ T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer.
Capietto AH; Martinet L; Fournié JJ
J Immunol; 2011 Jul; 187(2):1031-8. PubMed ID: 21670311
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
Fantini M; Arlen PM; Tsang KY
Front Immunol; 2023; 14():1275904. PubMed ID: 38077389
[TBL] [Abstract][Full Text] [Related]
19. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
